Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013


#166312

69pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . 

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma) .
  • A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) .
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bile Duct Cancer (Cholangiocarcinoma) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) 8
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Development by Companies 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Products under Development by Companies 16
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Products under Investigation by Universities/Institutes 17
Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development 18
AstraZeneca PLC 18
Novartis AG 19
Access Pharmaceuticals, Inc. 20
Marshall Edwards, Inc. 21
OncoTherapy Science, Inc. 22
Simcere Pharmaceutical Group 23
PCI Biotech AS 24
Provecs Medical GmbH 25
Mebiopharm Co., Ltd. 26
CellAct Pharma GmbH 27
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
vandetanib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ProLindac - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Im-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MEK-162 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Triphendiol - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
elpamotide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cancer Specific Antigen-Derived Peptide Vaccine + [gemcitabine] - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
gemcitabine + [cisplatin] - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fluorouracil - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
selumetinib sulfate + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
gemcitabine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
curcumin + [gemcitabine hydrochloride] - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Dendritic Cell Vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
JP-1584 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CAP-7.1 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Drug Profile Updates 59
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Discontinued Products 63
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Dormant Products 64
Bile Duct Cancer (Cholangiocarcinoma) Product Development Milestones 65
Featured News & Press Releases 65
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 65
Jan 10, 2012: Clinical Study Confirms Benitec's Gene-silencing Technology Is Safe And Effective In Fang Vaccine 66
Apr 07, 2009: Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial For The Trial REO 008 66

Appendix 68

Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

Number of Products Under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2013 8
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
AstraZeneca PLC, H1 2013 18
Novartis AG, H1 2013 19
Access Pharmaceuticals, Inc., H1 2013 20
Marshall Edwards, Inc., H1 2013 21
OncoTherapy Science, Inc., H1 2013 22
Simcere Pharmaceutical Group, H1 2013 23
PCI Biotech AS, H1 2013 24
Provecs Medical GmbH, H1 2013 25
Mebiopharm Co., Ltd., H1 2013 26
CellAct Pharma GmbH, H1 2013 27
Assessment by Monotherapy Products, H1 2013 28
Assessment by Combination Products, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 33
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Drug Profile Updates 59
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Discontinued Products 63
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Dormant Products 64
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2013 8
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 28
Assessment by Combination Products, H1 2013 29
Assessment by Route of Administration, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Molecule Type, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 33